PCN37 IMATINIB AND ITS CLINICAL ASSOCIATED OUTCOME IN CHRONIC MYELOID LEUKAEMIA PATIENTS

Abstract

Imatinib, a signal transduction inhibitor useful in the management of chronic myeloid leukemia (CML). There is a dearth of evidence available concerning the Imatinib and its associated outcomes in Indian CML patients. So, this study is aimed to assess the clinical outcomes associated with Imatinib. This study was conducted at Mahavir Cancer Sansthan & Research center Patna, India over a period of 10 months. Patients with confirmed CML diagnosis and were receiving Imatinib therapy were included. The toxicity was evaluated through CTCAE v 4.0 (common terminology criteria for adverse events) and compared with clinical outcomes. The EUTOS (European Treatment and Outcome Study) score was used to assess the complete cytogenetic response after 10 months. The data were analyzed through SPSS v 22. A total of 81 patients completed the study. The mean age of the patients was 38.8 ± 6.4 years and 35.80% were female. The majority of the patients belong to the age group of 41 – 60 years. Among BCR-ABL group patients, P210 kD (kilo Dalton) protein was found among 69 patients, P190 kD protein was found in 9 patients while dual fusion transcript of P210 kD and P190 kD protein was found in only 3 patients. Neutropenia was the most common adverse event associated with P210 kD protein determined through CTCAE v 4.0. The blast cell's content was more in the blast crisis phase as compared to the chronic and accelerated phase. The CML patients with P210 kD protein were at higher risk while P190 kD and coexistence were at a lower risk of progression to blastic and further to accelerated phase based on EUTOS score. It might be advisable to identify the BCR-ABL fusion transcript in CML patients when the patient started receiving Imatinib therapy in order to link the detected transcript with their clinical findings.